Investigator Award (IA) proposal ($300,000, two years) are our medium-size grants. These proposals have usually two (or three smaller) aims that describe work requiring two years to complete. They might have only one PI with or without collaborators. They can be considered equivalent to an NIH R21 grant.
This grant award would total $300,000 over two years. NETRF funds one to two Investigator Awards each year.
The Neuroendocrine Tumor Research Foundation (NETRF) seeks investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways.
- Applicants must have a faculty appointment (assistant professor and above).
- Applicants must have the skills, knowledge, and resources necessary to carry out the proposed research.
- Applicants must have an MD, PhD, MD/PhD or equivalent degree.
- Candidates must demonstrate a commitment to continue with NET research and the potential for further development in this area.
- Prior research in this field is not a prerequisite; in fact, the Foundation wishes to encourage expert scientists to enter the field. Applicants must, however, demonstrate a plan for continuing their research in NETs beyond the award period.
- Eligible organizations include public or private institutions, such as universities, colleges, hospitals, and laboratories, both domestic and international. Grants will be paid in US dollars.
- Projects that bring together investigators from diverse scientific disciplines are highly encouraged. For team applications, one recipient principal investigator and recipient institution must be selected. International applications are welcome.
- Awardees, as a condition of acceptance, will be required to attend the annual NETRF Research Symposium. Up to $2,000 may be allocated from the grant to offset the recipient’s registration and attendance costs for the Symposium.
NETRF will recruit for Investigator Award applications as part of our annual Request for Applications (RFA). Letters of Intent (LOI) are reviewed by the NETRF Board of Scientific Advisors, with applicants invited to submit full applications based on the quality of the project, support from the applicant’s institution, budget, and potential of the research to advance the field.
Grant recipients are required to submit biannual reports detailing scientific progress, research milestones achieved, and financial expenditures related to the project. These reports are reviewed by NETRF’s Scientific Review and Grants Administration team to ensure that funds are being properly spent and that sufficient progress is made throughout the grant term. Continued funding is contingent upon review of progress and achievement of relevant milestones.
The latest in NET News
Immunotherapy has been called one of the most significant advances in cancer in decades. While
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD,
https://www.youtube.com/watch?v=k1906SABias The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing